Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Marksans Pharma Limited, headquartered in India, is a prominent player in the global pharmaceutical industry, specialising in the development and manufacturing of generic and over-the-counter (OTC) products. Founded in 2001, the company has established a strong presence in key markets, including North America, Europe, and Asia, with a commitment to quality and innovation.
With a diverse portfolio that includes formulations across various therapeutic areas, Marksans Pharma stands out for its robust research and development capabilities. The company is known for its unique approach to product development, ensuring compliance with international regulatory standards. Marksans has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its position as a trusted name in the pharmaceutical sector.
-11 vs industry average
Marksans Pharma’s score of 31 is higher than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, Marksans Pharma reported total carbon emissions of approximately 21,868,979 kg CO2e, comprising 19,912,486 kg CO2e from Scope 1 and 1,530,493 kg CO2e from Scope 2 emissions. Notably, there were no reported Scope 3 emissions for this year.
The previous year, 2024, saw a total of approximately 23,130,250 kg CO2e, with all emissions attributed to Scope 1, as no Scope 2 or Scope 3 data was disclosed. In 2023, the company reported approximately 22,110,220 kg CO2e, again solely from Scope 1 emissions.
Marksans Pharma has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The absence of Scope 3 emissions data suggests that the company may need to enhance its reporting practices to align with industry standards.
Overall, while Marksans Pharma has made strides in tracking its emissions, the lack of comprehensive data and reduction initiatives highlights opportunities for improvement in its climate strategy.
No climate goals have been disclosed for Marksans Pharma yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more